QNCX · Quince Therapeutics, Inc. · Executive Compensation
$31.73
+2.37 (+8.07%)
At close · Oct 9
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Factoring in these potential cash payments, based on its current operating plan, the Company believes that its cash and cash equivalents balance will not be sufficient to fund operations and capital expenditures for at least the twelve months following the issuance of these unaudited condensed consolidated financial statements. Accordingly, the Company concluded that substantial doubt about the Company's ability to continue as a going concern continues to exist within one year after the date these financial statements are available to be issued.”View the 10-Q filed Aug 14, 2026
Market Cap
$32.27M
Shares
1.02M
Volume · Oct 9
138.74K
Avg daily vol (3M)
30.54K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Dirk Thye | Chief Executive Officer and Chief Medical Officer | $2,493,625 |
| Brendan Hannah | Chief Operating Officer, Chief Business Officer and Chief Compliance Officer | $1,263,075 |
| Charles Ryan | President | $1,144,100 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Dirk Thye | Chief Executive Officer and Chief Medical Officer | $2,732,125 |
| Brendan Hannah | Chief Operating Officer, Chief Business Officer and Chief Compliance Officer | $1,365,875 |
| Charles Ryan | President | $893,050 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Karen Smith | M.D., Ph.D. Former Chief Medical Officer | $1,347,920 |
| Dirk Thye | Chief Executive Officer and Chief Medical Officer | $1,330,500 |
| Brendan Hannah | Chief Business Officer, Chief Operating Officer and Chief Compliance Officer | $847,500 |
| Charles Ryan | President | $817,556 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Casey C. Lynch | Former President and Chief Executive Officer | $5,167,258 |
| Dirk Thye | Chief Executive Officer and Chief Medical Officer | $4,968,477 |
| Karen Smith | M.D., Ph.D. Former Chief Medical Officer | $3,485,274 |
| Christopher Lowe | Former Interim Chief Executive Officer, Chief Operating Officer, and Chief Financial Officer and Treasurer | $3,400,870 |
| Leslie Holsinger | Former Executive Vice President of Preclinical Development | $3,236,125 |
| Caryn McDowell | Former Chief Legal and Administrative Officer | $3,112,459 |
| Brendan Hannah | Chief Business Officer, Chief Operating Officer and Chief Compliance Officer | $1,152,926 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Christopher Lowe | Former Interim Chief Executive Officer, Chief Operating Officer, and Chief Financial Officer and Treasurer | $2,123,652 |
| Casey C. Lynch | Former President and Chief Executive Officer | $887,344 |
| Caryn McDowell | Former Chief Legal and Administrative Officer | $603,850 |
| Leslie Holsinger | Former Executive Vice President of Preclinical Development | $603,850 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Kristen Gafric | Senior Vice President, Legal and Administration, and Secretary | $1,952,937 |
| Michael Detke | Chief Medical Officer | $1,100,168 |
| Casey C. Lynch | Chief Executive Officer | $559,952 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Casey C. Lynch | Chief Executive Officer | $917,333 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Drayton Wise | Director | Appointed | 2026-10-09 |
| James Valentine | Director | Appointed | 2026-10-09 |
| Leone Patterson | Director | Appointed | 2026-10-09 |
| Catherine Bonuccelli | Director | Appointed | 2026-10-09 |
| Dirk Thye | member of the Company’s Board of Directors | Resigned | 2026-10-09 |
| Dirk Thye | Chief Executive Officer and Chief Medical Officer | Resigned | 2026-10-09 |
| Brendan Hannah | Chief Operating Officer, Chief Business Officer and Chief Compliance Officer | Resigned | 2026-10-09 |
| John Militello | Chief Financial Officer | Appointed | 2026-10-09 |
| Keith R. Fandrick | Chief Operating Officer | Appointed | 2026-10-09 |
| Brigette Roberts | Chief Executive Officer | Appointed | 2026-10-09 |
| Drayton Wise | Class II director | Appointed | 2026-10-09 |
| James Valentine | Class I director | Appointed | 2026-10-09 |
| Leone Patterson | Class III director | Appointed | 2026-10-09 |
| Catherine M. Bonuccelli | Class I director | Appointed | 2026-10-09 |
| Dirk Thye | director | Resigned | 2026-10-09 |
| Christopher Senner | director | Resigned | 2026-10-09 |
| David Lamond | director | Resigned | 2026-10-09 |
| June Bray | director | Resigned | 2026-10-09 |
| Keith Fandrick | Chief Operating Officer | Appointed | 2026-10-09 |
| John Militello | Chief Financial Officer | Appointed | 2026-10-09 |
| Brigette Roberts | Chief Executive Officer | Appointed | 2026-10-09 |
| Brendan Hannah | Chief Operating Officer, Chief Business Officer and Chief Compliance Officer | Resigned | 2026-10-09 |
| Dirk Thye | Chief Executive Officer and Chief Medical Officer | Resigned | 2026-10-09 |
| Drayton Wise | Class II director | Appointed | 2026-10-02 |
| James Valentine | Class I director | Appointed | 2026-10-02 |